Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Amazon
AMZN
|
+$738M |
| 2 |
Booking.com
BKNG
|
+$327M |
| 3 |
PepsiCo
PEP
|
+$282M |
| 4 |
Netflix
NFLX
|
+$263M |
| 5 |
Comcast
CMCSA
|
+$251M |
Top Sells
| 1 |
Exxon Mobil
XOM
|
+$726M |
| 2 |
Walmart
WMT
|
+$352M |
| 3 |
Becton Dickinson
BDX
|
+$331M |
| 4 |
GE Aerospace
GE
|
+$315M |
| 5 |
NetEase
NTES
|
+$307M |
Sector Composition
| 1 | Healthcare | 16.7% |
| 2 | Technology | 14.08% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.92% |
| 5 | Industrials | 8.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Northern Technologies International Corp
NTIC
$73.5M
| $697K | ﹤0.01% |
61,400
+7,800
| +15% | +$88.5K |
|
2802
First Trust Cloud Computing ETF
SKYY
$3.2B
| $697K | ﹤0.01% |
+14,400
| New | +$697K |
|
2803
Vanguard FTSE All-World ex-US ETF
VEU
$49.7B
| $696K | ﹤0.01% |
+12,800
| New | +$696K |
|
|
LITB
2804
LightInTheBox
LITB
$38M
| $692K | ﹤0.01% |
51,683
-20,917
| -29% | -$280K |
|
|
BLCM
2805
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $690K | ﹤0.01% |
+10,520
| New | +$690K |
|
2806
Coca-Cola Europacific Partners
CCEP
$40.7B
| $687K | ﹤0.01% |
16,500
-391,000
| -96% | -$16.3M |
|
2807
Zedge
ZDGE
$41.8M
| $681K | ﹤0.01% |
212,794
+4,900
| +2% | +$15.7K |
|
2808
Navigator Holdings
NVGS
$1.11B
| $676K | ﹤0.01% |
+57,500
| New | +$676K |
|
|
EGLT
2809
DELISTED
Egalet Corporation
EGLT
| $676K | ﹤0.01% |
1,072,400
+350,600
| +49% | +$221K |
|
2810
Peoples Bancorp of North Carolina
PEBK
$167M
| $671K | ﹤0.01% |
21,856
+3,638
| +20% | +$112K |
|
2811
Telefônica Brasil
VIV
$20B
| $670K | ﹤0.01% |
43,593
-269,360
| -86% | -$4.14M |
|
|
CRHM
2812
DELISTED
CRH Medical Corporation
CRHM
| $670K | ﹤0.01% |
262,800
-35,400
| -12% | -$90.3K |
|
2813
MediciNova
MNOV
$60.3M
| $666K | ﹤0.01% |
65,200
-14,300
| -18% | -$146K |
|
2814
Invesco FTSE RAFI Emerging Markets ETF
PXH
$1.64B
| $666K | ﹤0.01% |
28,326
+9,600
| +51% | +$226K |
|
|
CCM
2815
Concord Medical Services
CCM
$24.8M
| $665K | ﹤0.01% |
23,250
-610
| -3% | -$17.4K |
|
2816
CPI Aerostructures
CVU
$32.6M
| $665K | ﹤0.01% |
68,200
+10,300
| +18% | +$100K |
|
2817
Principal Financial Group
PFG
$18.4B
| $664K | ﹤0.01% |
10,900
-161,200
| -94% | -$9.82M |
|
|
ATHX
2818
DELISTED
Athersys, Inc. Common Stock
ATHX
| $664K | ﹤0.01% |
14,512
-13,740
| -49% | -$629K |
|
2819
Vince Holding
VNCE
$34M
| $661K | ﹤0.01% |
73,900
+13,100
| +22% | +$117K |
|
|
YTEN
2820
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $661K | ﹤0.01% |
353
+270
| +325% | +$506K |
|
2821
Inseego
INSG
$200M
| $661K | ﹤0.01% |
37,150
+4,450
| +14% | +$79.2K |
|
2822
iShares MSCI Switzerland ETF
EWL
$1.33B
| $653K | ﹤0.01% |
19,000
-28,600
| -60% | -$983K |
|
2823
Invesco S&P 500 Equal Weight Technology ETF
RSPT
$3.8B
| $651K | ﹤0.01% |
+43,000
| New | +$651K |
|
2824
ImmuCell
ICCC
$53.6M
| $645K | ﹤0.01% |
92,100
-1,800
| -2% | -$12.6K |
|
2825
Salarius Pharmaceuticals
SLRX
$2.7M
| $643K | ﹤0.01% |
2
+1
| +100% | +$322K |
|